Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4321129 | 0.96 | ADRA1A (0.50) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL4314418 | 0.95 | ADRA1A (0.49) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL5361174 | 0.95 | ADRA1A (0.49) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL5354341 | 0.93 | CHRM2 (0.44) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL6098673 | 0.92 | MAPT (0.52) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL2888870 | 0.88 | POLB (0.56) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL4344919 | 0.88 | CHRM2 (0.47) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL6718844 | 0.88 | MAPT (0.50) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL1895040 | 0.88 | CHRM2 (0.41) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL13645413 | 0.88 | MAPT (0.46) | CHRM2CHRM1DRD2ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288550-B2 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-7276515-B2 | Thioether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| CN-1253452-C | Thioether subsituted imidazoquinoline compound | 3M INNOVATIVE PROPERTIES CO (US) | 2006-04-26 | — | — | CN | disclosed |
| US-6949649-B2 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050209267-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-22 | — | — | US | disclosed |
| US-20050209268-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-22 | — | — | US | disclosed |
| US-6921826-B2 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1541572-A1 | Thioether substituted imidazoquinolines | 3M Innovative Properties Company (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1341791-B1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1451191-A1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040102471-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-27 | — | — | US | disclosed |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | disclosed |
| CN-1479738-A | thioether substituted imidazoquinoline compounds | 3M | 2004-03-03 | — | — | CN | disclosed |
| US-6667312-B2 | Useful as immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-23 | — | — | US | disclosed |
| US-6664264-B2 | Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| EP-1341791-A2 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| WO-2003050121-A1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-29 | — | — | US | disclosed |
| US-20020173655-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| WO-2002046192-A2 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209267-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | CHRM2 4686/4885CHRM1 4527/4885DRD2 4517/4885 |
| US-20050209268-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | CHRM2 4686/4885CHRM1 4527/4885DRD2 4517/4885 |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | CHRM2 4686/4885CHRM1 4527/4885DRD2 4517/4885 |
| US-20020173655-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | CHRM2 4686/4885CHRM1 4527/4885DRD2 4517/4885 |
| US-20040102471-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | CHRM2 4686/4885CHRM1 4527/4885DRD2 4517/4885 |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | CHRM2 4686/4885CHRM1 4527/4885DRD2 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.